Performance of continuous controlled attenuation parameter and liver stiffness measurement by the novel SmartExam in metabolic dysfunction‐associated steatotic liver disease
Liver International · 2024
DOI: 10.1111/liv.15862 ↗Kurz gefasst
Fachartikel in der Zeitschrift Liver International, 2024. Verfasst von Sherlot J Song und 10 weiteren Autor:innen. Beteiligte Einrichtung: Medical Data Analytics Centre, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China. Hauptthemen laut MEDLINE: Elasticity Imaging Techniques, Non-alcoholic Fatty Liver Disease, Metabolic Diseases. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: General Research Fund by the Hong Kong SAR Government (project reference 14106923), Direct grant from The Chinese University of Hong Kong (project reference 2022.031).
Abstract (Originalsprache)
Background & Aims FibroScan® Expert 630 and FibroScan® Mini+430 are novel vibration‐controlled transient elastography devices equipped with the same SmartExam software, which allows continuous measurement of controlled attenuation parameter (CAP) during the entire examination. This study aims to compare the CAP variabilities and the quantification for liver fibrosis and steatosis between the conventional FibroScan and the SmartExam‐equipped machines in patients with metabolic dysfunction‐associated steatotic liver disease (MASLD).
Methods
This retrospective study included 118 patients with biopsy‐proven MASLD who underwent liver biopsy at two tertiary centres between 2021 and 2023. Liver stiffness and steatosis measurements were performed using both FibroScan machines and M and XL probes for each individual. Liver histology was used as the reference standard for liver fibrosis and steatosis staging.
Results
Standard deviations of continuous CAP (cCAP) were significantly lower than those of CAP for all probes ( p < .0001). CAP variability was significantly associated with body mass index ( p < .01), probe selection ( p < .001) as well as the random effect of centre. Only the effect of probe selection ( p < .001) was significantly associated with cCAP variability. No significant difference was found in the performance of staging liver fibrosis and steatosis between two types of machines at the same cut‐offs.
Conclusions
The SmartExam‐based VCTE reduces the variability of CAP measurement and achieves a similar accuracy as the FibroScan 502 device for the estimation of both hepatic steatosis and fibrosis. Future studies should determine if cCAP is a better tool to monitor changes in steatosis than the original CAP.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Medical Data Analytics Centre, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China.
- State Key Laboratory of Digestive Disease, Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong, China.
- Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
- Department of Anatomical and Cellular Pathology, The Chinese University of Hong Kong, Hong Kong, China.
ORCID-Profile: Lilian Y Liang, Jimmy C T Lai, Grace L H Wong, Vincent W S Wong, Terry C F Yip
Förderung
- General Research Fund by the Hong Kong SAR Government (project reference 14106923)
- Direct grant from The Chinese University of Hong Kong (project reference 2022.031)
Zitieren
APA
Song, S. J., Nogami, A., Liang, L. Y., Yoneda, M., Leung, H. H. W., Nakajima, A., Lai, J. C. T., Wong, G. L. H., Shu, S. S. T., Wong, V. W. S., & Yip, T. C. F. (2024). Performance of continuous controlled attenuation parameter and liver stiffness measurement by the novel SmartExam in metabolic dysfunction‐associated steatotic liver disease. Liver International. https://doi.org/10.1111/liv.15862
Vancouver
Song SJ, Nogami A, Liang LY, Yoneda M, Leung HHW, Nakajima A, et al. Performance of continuous controlled attenuation parameter and liver stiffness measurement by the novel SmartExam in metabolic dysfunction‐associated steatotic liver disease. Liver International. 2024. doi:10.1111/liv.15862
BibTeX
@article{Song2024,
author = {Song, Sherlot J and Nogami, Asako and Liang, Lilian Y and Yoneda, Masato and Leung, Howard H W and Nakajima, Atsushi and Lai, Jimmy C T and Wong, Grace L H and Shu, Sally S T and Wong, Vincent W S and Yip, Terry C F},
title = {Performance of continuous controlled attenuation parameter and liver stiffness measurement by the novel SmartExam in metabolic dysfunction‐associated steatotic liver disease},
journal = {Liver International},
year = {2024},
doi = {10.1111/liv.15862}
}
EUVIMED